Identifying FDA-approved drugs with multimodal properties against COVID-19 using a data-driven approach and a lung organoid model of SARS-CoV-2 entry

被引：0
|
作者：
Rodrigo R. R. Duarte
Dennis C. Copertino
Luis P. Iñiguez
Jez L. Marston
Yaron Bram
Yuling Han
Robert E. Schwartz
Shuibing Chen
Douglas F. Nixon
Timothy R. Powell
机构：
[1] Weill Cornell Medicine,Division of Infectious Diseases, Department of Medicine
[2] Cornell University,Social, Genetic & Developmental Psychiatry Centre, Institute of Psychiatry, Psychology & Neuroscience
[3] King’s College London,Division of Gastroenterology and Hepatology, Department of Medicine
[4] Weill Cornell Medicine,Department of Surgery, Weill Cornell Medicine
[5] Cornell University,Department of Physiology, Biophysics and Systems Biology, Weill Cornell Medicine
[6] Cornell University,undefined
[7] Cornell University,undefined
来源：
Molecular Medicine | 2021年 / 27卷
关键词：
Drug repositioning; Lung organoids; Pandemic; COVID-19; Connectivity mapping; Chemoinformatics; Molecular docking; Drug screening; Drug testing; Atorvastatin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Developing drugs against essential proteins of SARS-CoV-2 for the treatment of COVID-19
    Bajaj, Teena
    BIOPHYSICAL JOURNAL, 2022, 121 (03) : 7 - 7
  • [22] Neurological Effects of SARS-CoV-2 and Neurotoxicity of Antiviral Drugs Against COVID-19
    Unlu, Busra
    Simsek, Rahime
    Kose, Selinay Basak Erdemli
    Yirun, Anil
    Erkekoglu, Pinar
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2022, 22 (02) : 213 - 231
  • [23] Identification of FDA-approved drugs against SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) through computational virtual screening
    Dhananjay Jade
    Areej Alzahrani
    William Critchley
    Sreenivasan Ponnambalam
    Michael A. Harrison
    Structural Chemistry, 2023, 34 : 1005 - 1019
  • [24] Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods
    Ginex, Tiziana
    Garaigorta, Urtzi
    Ramirez, David
    Castro, Victoria
    Nozal, Vanesa
    Maestro, Ines
    Garcia-Carceles, Javier
    Campillo, Nuria E.
    Martinez, Ana
    Gastaminza, Pablo
    Gil, Carmen
    PHARMACEUTICALS, 2021, 14 (04)
  • [25] Identification of FDA-approved drugs against SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) through computational virtual screening
    Jade, Dhananjay
    Alzahrani, Areej
    Critchley, William
    Ponnambalam, Sreenivasan
    Harrison, Michael A.
    STRUCTURAL CHEMISTRY, 2023, 34 (03) : 1005 - 1019
  • [26] An insight into the inhibitory mechanism of phytochemicals and FDA-approved drugs on the ACE2-Spike complex of SARS-CoV-2 using computational methods
    Jani, Vinod
    Koulgi, Shruti
    Uppuladinne, V. N. Mallikarjunachari
    Sonavane, Uddhavesh
    Joshi, Rajendra
    CHEMICAL PAPERS, 2021, 75 (09) : 4625 - 4648
  • [27] An insight into the inhibitory mechanism of phytochemicals and FDA-approved drugs on the ACE2–Spike complex of SARS-CoV-2 using computational methods
    Vinod Jani
    Shruti Koulgi
    V. N. Mallikarjunachari Uppuladinne
    Uddhavesh Sonavane
    Rajendra Joshi
    Chemical Papers, 2021, 75 : 4625 - 4648
  • [28] Targeting major SARS-CoV-2 protease to develop effective drugs against COVID-19
    Ladoux, Annie
    Azoulay, Stephane
    Dani, Christian
    M S-MEDECINE SCIENCES, 2020, 36 (6-7): : 555 - 558
  • [29] Repurposing drugs to fight COVID-19: SARS-CoV-2 envelope targeting by clinically approved porphyrins and analogues
    Mendonca, D. A.
    Cadima-Couto, I.
    Schaberle, F. A.
    Veiga, A. S.
    Arnaut, L. G.
    Castanho, M. A. R. B.
    Cruz-Oliveira, C.
    FEBS OPEN BIO, 2022, 12 : 166 - 166
  • [30] Letter to the Editor in response to the article 'Candidate drugs against SARS-CoV-2 and COVID-19'
    Campesi, Ilaria
    Montella, Andrea
    Franconi, Flavia
    PHARMACOLOGICAL RESEARCH, 2021, 163
12345